Press Releases Latest May 31, 2022 Theratechnologies Announces New Head of Investor Relations Press Releases Year None2022202120202019201820172016201520142013 Apr 01, 2021 Theratechnologies to Announce Financial Results for Its First Quarter Fiscal 2021 Apr 10, 2021 Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types Mar 29, 2021 Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Mar 20, 2021 Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation Mar 10, 2021 Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021 Feb 25, 2021 Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference Feb 25, 2021 Theratechnologies Announces Fourth-Quarter And Fiscal-Year 2020 Financial Results Feb 11, 2021 Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020 Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 41 - 50 of 281
Apr 10, 2021 Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types
Mar 29, 2021 Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets
Mar 24, 2021 Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors
Mar 20, 2021 Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect On Immune Response Linked To Liver Inflammation
Mar 10, 2021 Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021
Feb 04, 2021 Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers
